Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06051617 · ClinicalTrials.gov registry record · Phase 3
Seladelpar in Subjects With Primary Biliary Cholangitis (PBC) and Compensated Cirrhosis
A Phase 3 study of Primary Biliary Cholangitis, sponsored by Gilead Sciences.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 318
- Enrollment target
- 20
- Study locations
NCT06051617 is a Phase 3 study of Primary Biliary Cholangitis that is actively recruiting participants, run by Gilead Sciences. The registered enrollment target is 318 participants, above the 167-participant average among 8 other Primary Biliary Cholangitis trials with a reported enrollment target (90% higher). The trial reports 20 study locations across 8 states.
The verdict
NCT06051617, a Phase 3 study of Primary Biliary Cholangitis, is actively recruiting participants, sponsored by Gilead Sciences.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 318 participants
- Enrollment target
- 20
- Study locations
Study Summary
To Evaluate the Effect of Seladelpar on Clinical Outcomes in Patients with Primary Biliary Cholangitis (PBC) and Compensated Cirrhosis.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Seladelpar
Study Locations (20)
California
- OM Research LLC - Lancaster
- SCPMG/Kaiser Permanente Los Angeles Medical Center - Los Angeles
- Cedar Sinai Medical Center - Los Angeles
- California Liver Research Institute - Pasadena
- Stanford University - Redwood City
- University of California, Davis Medical Center - Sacramento
- California Pacific Medical Center - Sutter Pacific Medical Foundation - San Francisco
- Connie Frank Transplant Center at UCSF - San Francisco
Florida
- Covenant Metabolic Specialists, LLC - Fort Myers
- Schiff Center for Liver Diseases/University of Miami - Miami
- Covenant Metabolic Specialists, LLC - Sarasota
- Florida Research Institute - Tampa
Illinois
- Northwestern University - Chicago
- University of Chicago Medical Center - Chicago
Louisiana
- Ochsner Clinic Foundation - Jefferson
- University Health System - East Jefferson General Hospital Campus - New Orleans
Arizona
- St. Joseph's Hospital and Medical Center - 350 W. Thomas - Phoenix
Georgia
- Piedmont Atlanta Hospital / Piedmont Transplant Institute - Atlanta
Iowa
- University Of Iowa Hospitals And Clinics - Iowa City
Kentucky
- University of Louisville, Clinical Trials Unit - Louisville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 318 participants |
| Start Date | 2023-09-07 |
| Est. Completion | 2030-08 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06051617
The ClinicalTrials.gov registry entry for NCT06051617 describes a study currently listed as recruiting, categorized as Phase 3. The registered enrollment target is 318 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 167-participant average among 8 other Primary Biliary Cholangitis trials with a reported enrollment target (90% higher). The listed sponsor is Gilead Sciences, which has 504 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Primary Biliary Cholangitis appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT06051617 reports 20 study locations spanning 8 distinct geographic areas - top geographies include California, Florida, Illinois.
Frequently Asked Questions
What is clinical trial NCT06051617 about?
NCT06051617 is a clinical study titled "Seladelpar in Subjects With Primary Biliary Cholangitis (PBC) and Compensated Cirrhosis". To Evaluate the Effect of Seladelpar on Clinical Outcomes in Patients with Primary Biliary Cholangitis (PBC) and Compensated Cirrhosis.
What is the current status of trial NCT06051617?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 318 participants. The study started on 2023-09-07. Estimated completion is 2030-08.
What conditions does trial NCT06051617 study?
This clinical trial studies the following conditions: Primary Biliary Cholangitis.
What interventions are being tested in trial NCT06051617?
The interventions under investigation include: Placebo (DRUG), Seladelpar (DRUG).
Who is sponsoring clinical trial NCT06051617?
This trial is sponsored by Gilead Sciences, which has 504 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06051617 being conducted?
This trial has 20 study locations across Arizona, California, Florida, Georgia, Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Primary Biliary Cholangitis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Open-Label Extension Study of Saroglitazar Magnesium in Participants With Primary Biliary Cholangitis
RECRUITING · Phase 3
-
A Study of Elafibranor in Adults With Primary Biliary Cholangitis and Inadequate Response or Intolerance to Ursodeoxycholic Acid.
ACTIVE NOT RECRUITING · Phase 3
-
Intended to Determine the Effects of Seladelpar on Normalization of Alkaline Phosphatase Levels in Subjects With Primary Biliary Cholangitis (PBC)
ACTIVE NOT RECRUITING · Phase 3
-
ENHANCE: Seladelpar in Subjects With Primary Biliary Cholangitis (PBC) and an Inadequate Response to or an Intolerance to Ursodeoxycholic Acid (UDCA)
COMPLETED · Phase 3
-
A Study to Evaluate Efficacy and Safety of an Investigational Drug Named Volixibat in Patients With Itching Caused by Primary Biliary Cholangitis
RECRUITING · Phase 2
-
A Study Observing Everyday Effectiveness and Safety of the Drug Elafibranor in Participants With Primary Biliary Cholangitis Who Are Receiving Ongoing Treatment
RECRUITING
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.